-The Hindu Business Line The recent deaths in Maharashtra once again affirm that highly toxic agrochemicals are freely sold across the counter Last month about 40 farmers died and more than 700 were hospitalised in Maharashtra due pesticide poisoning. Initial reports suggest that the deaths are due to monochrotophos. This is a highly toxic chemical that has been banned in more than 60 countries but is still allowed to be sold in...

-The Times of India NEW DELHI: Cancer cases as well as mortality are increasing rapidly among Indian women, primarily because of low awareness and late detection. India accounts for the third highest number of cancer cases among women after China and the US, growing annually at 4.5-5%, new data shows. According to a report 'Call for Action: Expanding cancer care for women in India, 2017', cancer among women in India is estimated...

-The Telegraph New Delhi: India's drug pricing rules allow companies to inflate the maximum retail prices of medicines, including life-saving drugs, costing patients thousands of additional rupees while offering slices of the profits to stockists, chemists, and hospitals. Quotations received by hospitals from drug companies' representatives offering discounts on maximum retail prices (MRPs) of medicines provide what some doctors and patients' rights advocates say is fresh evidence for excessive profiteering in India's...

-The Telegraph New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries. It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat Breast Cancer. The pre-qualification process is a mechanism...

-The Times of India Cancer drugs, being the top focus for research and development, corner the lion's share of medicines launched globally, yet only a handful make it to developing countries like India. Only seven oncology drugs were introduced in India over five years (2010-2014), when nearly 50 breakthrough therapies were rolled out globally. The disparity in availability of oncology therapies becomes even more stark over a 10-year period (2006-2016), with not even...